We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Dendreon’s Provenge Prolongs Survival in Advanced Prostate Cancer
Dendreon’s Provenge Prolongs Survival in Advanced Prostate Cancer
April 29, 2009
Dendreon has provided further support for its claim that its cancer vaccine Provenge significantly improved overall survival in men with advanced prostate cancer compared with those on a placebo, in a Phase III study.